MediSynergics reports positive ongoing preclinical development of “ketamine derivative” compounds MS-168 and MS-227 in pain, anxiety, behavior acute toxicity pharmacology, in vitro ADME, and structural elucidation studies.
Dennis Godek, CEO, says the company is very encouraged with the data for both compounds and believes MediSynergics library of ketamine derivatives offer additional CNS development opportunities.more